In fibroblasts derived from FRDA patients, RTA408 exerts this effect by increasing NRF2 mRNA and protein expression and the subsequent induction of NRF2-target genes (i.e., NQO1, HO-1, and GCL), with no significant changes in FXN mRNA expression [126]. The gene discussed is FXN; the disease is Friedreich ataxia.